GlaxoSmithKline Says Phase-3 Study for Sirukumab Meets Main Targets
08 June 2016 - 9:52PM
Dow Jones News
LONDON--GlaxoSmithKline PLC (GSK.LN) Wednesday said the Phase-3
study for sirukumab, a human antibody designed for patients with
severely active rheumatoid arthritis, met its two most important
targets, and added that it is on track to submit the regulatory
applications in the third quarter of 2016.
Sirukumab is being co-developed as part of a collaboration with
Janssen Biologics in Ireland, said the bio-pharmaceutical
company.
The main two end points showed that the inhibition of
radiographic progression, or joint destruction, was significantly
greater among sirukumab-treated patients, and that at least 20%
improvement in rheumatoid arthritis signs and symptoms was achieved
by more than half of patients at week 16, the company said.
Shares at 1120 GMT down 12 pence, or 0.8%, at 1450 pence valuing
the company at 70.64 billion pounds ($102.4 billion).
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter
@OlgaCotaga
(END) Dow Jones Newswires
June 08, 2016 07:37 ET (11:37 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024